Skip to main content
OpenTrials
Completed

NCT Number: NCT05009407

CD160 Expression in Corneal Vessels

Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Corneal Graft Rejection Angiogenesis CD160 Lymphangiogenesis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Damien JOLLY

Reims, France

About this study

After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included.

Routine general and eye examination including cornea photographs will be performed.

During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-year-old or more patients
  • enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France
  • considered able to give an informed written consent exclusion criteria :
  • none

Treatment and study plan

Immunohistochemistry and clinical analyses on patients and corneas

Biological

Immunohistochemistry and clinical analyses on patients and corneas

Primary outcomes

  1. Micro-vascular densities

    Time frame: 1 year

    neovascularization scores quantification of blood (anti-ERG+/anti-D2-40-) and lymphatic (anti-ERG+/anti-D2-40+) vascular structures ; Percentages of those vascular structures marked with anti-CD160

Secondary outcomes

  1. Percentages of those vascular structures marked with anti-CD160 and/or CD105 and/or aSMA

    Time frame: 1 year

  2. Evaluation of clinical blood vascular densities on photographs with help of ImageJ software

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

CHU de Reims

Other

Registry information

Official study title

CD160 Ans Corneal Graft: Expression in Corneal Vessels

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Aug 17, 2021
Registry last updated
Feb 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.